Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
M33 Growth is a venture capital firm based in Boston, Massachusetts, founded between 2015 and 2017. The firm focuses on partnering with bootstrapped entrepreneurs, providing capital and resources to help businesses accelerate growth and achieve market leadership. M33 Growth has a strong pedigree, with its founders having backgrounds at General Catalyst and Bain Capital, which enhances its ability to support portfolio companies effectively.
As of now, M33 Growth manages approximately $780 million across three funds, with the latest fund, Fund III, closing at $340 million in January 2023. The firm primarily invests in North America and has a portfolio of 10 companies, emphasizing its commitment to founder-owned businesses, particularly in vertical software and healthcare sectors. M33 Growth has established a reputation for its strategic support in sales, marketing, mergers and acquisitions, and talent acquisition, which are critical for scaling operations.
Notable milestones include the successful IPO of The Oncology Institute of Hope & Innovation on NASDAQ, showcasing the firm’s ability to guide companies to significant exits. M33 Growth operates from its headquarters at 888 Boylston Street, Suite 500, Boston, MA 02199-8202, with additional operations in Parkville, Missouri.
M33 Growth invests in founder-owned, bootstrapped businesses, primarily focusing on vertical software and healthcare sectors. The firm targets companies at various stages, including seed, Series A, and growth equity, with a particular emphasis on growth-stage investments. The typical check size ranges from $1 million to $20 million, depending on the stage and needs of the company.
The firm seeks to partner with experienced operating executives and provides tailored support in areas such as sales and marketing, mergers and acquisitions, and talent acquisition. M33 Growth aims to help its portfolio companies scale their operations and optimize their go-to-market strategies. The firm’s investment thesis centers on supporting bootstrapped companies that are often seeking their first institutional capital, allowing them to maintain control while accessing the resources necessary for growth.
In addition to its focus on vertical software and healthcare, M33 Growth is open to investing in tech-enabled services that complement its existing portfolio. The firm’s approach is characterized by a hands-on involvement in the growth journey of its investments, ensuring that they achieve significant market leadership.
M33 Growth has a diverse portfolio of 10 companies, showcasing its focus on vertical software and healthcare. Notable portfolio companies include:
Additionally, M33 Growth has achieved notable exits, including the IPO of The Oncology Institute of Hope & Innovation on NASDAQ under the ticker TOI. The firm also facilitated the acquisition of Assuricare by Livtech and Mize by Syncron, indicating its active role in supporting growth and market leadership for its portfolio companies.
Mike Anello - Founder. Anello has a strong background in venture capital and entrepreneurship, contributing to M33 Growth's strategic direction.
Gabe Ling - Co-Founder & Managing Director. Ling previously served as a partner at General Catalyst, focusing on software, business services, and healthcare services/IT.
Brian Shortsleeve - Co-Founder & Managing Director. Shortsleeve has experience as the former General Manager and COO of MBTA and has worked at Bain Capital.
Rachel Carducci - CFO. Carducci brings financial expertise to the firm, ensuring sound fiscal management and strategic financial planning.
Kara Hollis - Executive Director. Hollis plays a key role in overseeing operations and strategic initiatives within the firm.
Ryan Kubacki - Operating Partner. Kubacki focuses on operational excellence and supports portfolio companies in scaling their businesses.
Tommy Belton, Meghan Curtis, Nate Ellis, Joe Kellett, and Hannah Quartner - all serve as VPs in Platforms & Strategic M&A, contributing to the firm's investment strategy and portfolio management.
Andrew Pearsons - Value Creation Partner. Pearsons focuses on maximizing value for portfolio companies through strategic initiatives.
Lauren Slutsky - Head of Talent. Slutsky is responsible for talent acquisition and management within the firm and its portfolio companies.
To pitch M33 Growth, founders should visit their website at m33growth.com. The firm prefers detailed pitch decks that include information about the business model, market analysis, and the founding team. A clear articulation of the company's growth strategy and how M33 Growth's resources can facilitate that growth is essential.
Response times can vary, but founders should expect to hear back within a few weeks after submitting their pitch. M33 Growth values warm introductions, so leveraging connections within their network can enhance the chances of a successful pitch.
On January 15, 2023, M33 Growth closed its third fund at $340 million, signaling strong support from limited partners and a commitment to investing in bootstrapped companies.
In August 2024, M33 Growth made a strategic investment in Clear Demand, a company specializing in AI price and promotion optimization for retail.
In February 2025, M33 Growth partnered with Pediatrica Health Group to enhance pediatric primary care services, marking a significant step in their healthcare investment strategy.
Additionally, M33 Growth facilitated the acquisition of Assuricare by Livtech, which provides long-term care registry and agency software, demonstrating the firm's active involvement in M&A activities.
What are M33 Growth's investment criteria?
M33 Growth focuses on investing in founder-owned, bootstrapped companies primarily in vertical software and healthcare sectors. The firm looks for businesses that are at the seed, Series A, or growth equity stages, with a preference for those that have demonstrated market traction and a clear path to scaling operations.
How can I pitch to M33 Growth?
Founders can pitch M33 Growth through their website at m33growth.com. It is advisable to include a detailed business plan, market analysis, and information about the founding team in the pitch deck.
What makes M33 Growth different from other VC firms?
M33 Growth specializes in partnering with bootstrapped, founder-owned companies, often providing their first institutional capital. The firm emphasizes a hands-on approach, offering strategic support in sales, marketing, and M&A, which distinguishes it from traditional venture capital firms.
What is the geographic scope of M33 Growth's investments?
The firm primarily invests in North America, focusing on companies that are well-positioned within the vertical software and healthcare sectors.
What is M33 Growth's post-investment involvement like?
M33 Growth actively engages with its portfolio companies, providing resources and expertise in scaling operations, optimizing go-to-market strategies, and recruiting leadership teams. The firm aims to ensure that its investments achieve significant growth and market leadership.
What is the typical check size for investments?
M33 Growth typically invests between $1 million and $20 million, depending on the stage of the company and its specific needs for growth capital.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.